Conversations in Drug Development Trends

NOVEMBER 12, 2024

For example, once considered incurable and terminal, patients with sickle cell disease may reach new summits in their lives with gene editing technologies such as CRISPR to repair affected DNA and, in some cases, functionally cure the condition. Operationalizing these trials requires proactive and flawless management at every stage.

Therapies 72

Therapies Clinical Supply Clinical Trials Trials 72

BioPharma Drive: Drug Pricing

JUNE 9, 2025

Deep Dive Library Events Press Releases Topics Sign up Search Sign up Search Pharma Biotech FDA Clinical Trials Deals Drug Pricing Gene Therapy An article from Sponsored The golden era of GLP-1 drugs: How will it impact medicine and society? You can unsubscribe at anytime. Its new CEO has to figure out what’s next. TechTarget, Inc.s

Clinical Trials 146

Clinical Trials Drugs Therapies Clinical Supply 146

BioPharma Drive: Drug Pricing

JUNE 9, 2025

2 Natural Killer Cells Show Promise in Alzheimer’s Trials --> Ep. 3 Digital Behavioral Therapy for Fibromyalgia In Episode 3 of the Trial Trailblazers podcast, discover how a company transformed behavioral therapy into an FDA-approved digital treatment for fibromyalgia. ⬆ Ep. 3 Digital Behavioral Therapy for Fibromyalgia Ep.

Trials 130

Trials Clinical Supply Clinical Trials Therapies 130

Drug Target Review

MAY 27, 2025

Melika Davis, Senior Vice President and Global Head of Clinical Operations at BeOne , has built a career at the intersection of science and operational leadership. Today, my team is advancing more than 100 trials supporting an expansive pipeline of innovative molecules, striving to improve outcomes for people with cancer around the world.

Clinical Trials 52

Clinical Trials Molecular Biology Trials Clinical Supply 52

BioPharma Drive: Drug Pricing

JUNE 5, 2025

Deep Dive Library Events Press Releases Topics Sign up Search Sign up Search Pharma Biotech FDA Clinical Trials Deals Drug Pricing Gene Therapy An article from FDA’s AI tool ‘Elsa’ is here, and the industry has questions The agency has provided only limited details about its AI pilot as it advances an “aggressive timeline” for the tool’s rollout.

FDA 130

FDA Therapies Clinical Supply Licensing 130